Tango Therapeutics Income Statement (2020-2025) | TNGX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 11.26M6.17M6.39M18.15M6.79M5.72M5.76M5.77M6.92M6.41M5.77M14.60M10.73M5.43M6.47M19.88M11.61M4.12M5.39M3.18M53.81M
Operating items
Research & Development 12.98M15.06M15.00M19.08M21.92M21.63M24.33M23.74M28.74M29.09M28.04M28.67M27.15M31.34M38.06M38.65M33.26M33.94M36.44M32.81M30.82M
Selling, General & Administrative 472.002.52M0.11M3.47M3.63M4.43M6.07M6.81M7.23M8.10M7.89M8.01M9.17M9.21M9.11M10.66M10.77M11.22M11.09M11.48M11.34M8.92M
Other Operating Expenses 2.91M
Operating Expenses 472.0015.49M18.08M18.47M22.71M26.36M27.70M31.14M30.97M36.84M36.98M36.05M37.84M36.36M40.44M48.73M49.43M44.48M45.03M47.92M44.15M39.74M
Operating Income -472.00-26.76M-0.18M-12.08M-4.56M-19.57M-21.98M-25.38M-25.20M-29.92M-30.57M-30.29M-23.25M-25.63M-35.01M-42.26M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M
EBIT -472.00-26.76M-0.18M-12.08M-4.56M-19.57M-21.98M-25.38M-25.20M-29.92M-30.57M-30.29M-23.25M-25.63M-35.01M-42.26M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M
Non-operating items
Non Operating Investment Income 0.01M-0.01M0.01M-0.03M-0.01M-0.76M-2.65M-0.94M-0.51M1.15M1.50M0.68M0.84M0.87M-0.44M
Interest & Investment Income 0.07M0.03M0.01M
Other Non Operating Income 0.00M0.00M-0.06M-0.06M-0.05M-0.08M-0.05M0.05M0.52M0.97M1.22M1.15M1.51M2.06M2.18M2.00M1.96M1.48M1.07M0.91M0.70M
Non Operating Income -0.05M0.07M-0.06M-0.06M-0.05M-0.08M0.17M0.35M0.87M1.56M2.28M2.60M3.39M4.30M4.38M4.07M3.77M3.29M2.69M2.15M1.80M
Net income details
EBT -472.00-26.80M-0.12M-12.03M-4.51M-19.53M-21.87M-25.21M-24.86M-29.05M-29.01M-28.01M-20.65M-22.24M-30.72M-37.87M-25.49M-29.11M-37.62M-39.84M-38.82M15.87M
Tax Provisions 0.01M0.07M-0.02M0.06M0.18M0.00M0.10M0.10M0.02M0.03M0.04M0.07M0.05M0.01M0.03M0.04M-0.01M
Profit After Tax -472.00-26.80M-0.12M-12.11M-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.67M-39.88M-38.85M15.88M
Income from Continuing Operations -472.00-26.80M-0.12M-12.11M-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.11M-28.01M-20.75M-22.26M-30.75M-37.91M-25.55M-29.17M-37.63M-39.88M-38.85M15.88M
Consolidated Net Income -472.00-26.80M-0.12M-12.11M-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.11M-28.01M-20.75M-22.26M-30.75M-37.91M-25.55M-29.17M-37.63M-39.88M-38.85M15.88M
Income towards Parent Company -472.00-26.80M-0.12M-12.11M-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.11M-28.01M-20.75M-22.26M-30.75M-37.91M-25.55M-29.17M-37.63M-39.88M-38.85M15.88M
Net Income towards Common Stockholders -472.00-26.80M-0.12M-12.11M-0.24M-19.59M-22.05M-25.21M-24.86M-29.05M-29.11M-28.01M-20.75M-22.26M-30.75M-37.91M-25.55M-29.17M-37.63M-39.88M-38.85M15.88M
Additional items
EPS (Basic) 0.00-0.76-0.01-0.29-0.09-0.28-0.26-0.29-0.28-0.33-0.33-0.32-0.23-0.23-0.30-0.35-0.24-0.27-0.34-0.36-0.350.14
EPS (Weighted Average and Diluted) -0.28-0.28-0.26-0.29-0.28-0.33-0.33-0.32-0.23-0.23-0.30-0.35-0.24-0.27-0.34-0.36-0.350.13
Shares Outstanding (Weighted Average) 16.07M16.07M21.38M21.38M87.47M87.47M87.55M87.71M87.90M88.04M88.18M88.20M88.41M88.47M101.99M106.72M106.85M107.14M107.42M108.11M108.39M111.26M
Shares Outstanding (Diluted Average) 48.52M70.16M62.11M87.67M87.84M87.89M87.82M88.19M88.35M97.03M94.57M108.17M108.69M108.99M109.23M110.30M110.54M
EBITDA -472.00-26.79M-8.87M-12.09M-4.52M-19.60M-22.80M-27.85M-25.80M-29.56M-27.91M-26.50M-20.03M-21.43M-29.90M-38.36M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M
Tax Rate 0.47%